GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » Long-Term Capital Lease Obligation

Idorsia (LTS:0RQE) Long-Term Capital Lease Obligation : CHF68.5 Mil (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia Long-Term Capital Lease Obligation?

Idorsia's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was CHF68.5 Mil.

Idorsia's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 (CHF86.0 Mil) to Jun. 2023 (CHF70.7 Mil) and declined from Jun. 2023 (CHF70.7 Mil) to Sep. 2023 (CHF68.5 Mil).

Idorsia's annual Long-Term Capital Lease Obligation increased from Dec. 2020 (CHF43.1 Mil) to Dec. 2021 (CHF60.6 Mil) and increased from Dec. 2021 (CHF60.6 Mil) to Dec. 2022 (CHF88.6 Mil).


Idorsia Long-Term Capital Lease Obligation Historical Data

The historical data trend for Idorsia's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Long-Term Capital Lease Obligation Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial - 43.58 43.11 60.56 88.64

Idorsia Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.86 88.64 85.98 70.67 68.50

Idorsia  (LTS:0RQE) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Idorsia Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Idorsia's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Idorsia (LTS:0RQE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia (LTS:0RQE) Headlines

No Headlines